Apologies hit post too early. OD designation seems very unlikely. If they had a larger trial, and included hand-use, ambulation and removed Anxiety as a measure of efficacy they'd have better luck. Our P2 results weren't *that* strong but our trial design was less than ideal given GI issues, dosage and we've learnt how Daybue works in the real world (slowly increasing dosage) - and that the affect seems to compound with time.
Neuren Media and Analyst Coverage, page-1114
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.51 |
Change
-0.300(2.17%) |
Mkt cap ! $1.751B | |||
| Open | High | Low | Value | Volume |
| $13.82 | $13.91 | $13.51 | $2.248M | 164.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1192 | $13.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.52 | 351 | 4 |
View Market Depth
| Last trade - 13.46pm 11/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |